share_log

Vir Biotechnology Completes Enrollment Of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial

Vir Biotechnology Completes Enrollment Of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial

Vir Biotechnology 完成 2 期慢性肝炎 Delta SOLSTICE 试验
Moomoo 24/7 ·  03/05 08:06

– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter –

— 超过60名参与者分成了另外两个群组；初步数据预计将在第二季度公布—

– Approximately 50% of participants have compensated cirrhosis –

— 大约 50% 的参与者已补偿性肝硬化 —

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发